Sionna Therapeutics (NASDAQ:SION) Rating Lowered to Hold at Lifesci Capital

Sionna Therapeutics (NASDAQ:SION) was downgraded by investment analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Several other equities research analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Wednesday, August 5th. Stifel Nicolaus reiterated a “hold” rating and issued a $7.00 price objective on shares of Sionna Therapeutics in a research report on Monday. Wall Street Zen lowered shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Citizens Jmp lowered shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday. Finally, Royal Bank Of Canada upgraded shares of Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price objective for the company in a research note on Monday. One investment analyst has rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $42.22.

Sionna Therapeutics Stock Performance

SION opened at $5.10 on Monday. The firm’s fifty day moving average is $40.99 and its two-hundred day moving average is $39.92. The firm has a market cap of $230.58 million, a PE ratio of -2.34 and a beta of 1.32. Sionna Therapeutics has a twelve month low of $4.01 and a twelve month high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). Equities analysts forecast that Sionna Therapeutics will post -2.66 EPS for the current fiscal year.

Insider Buying and Selling at Sionna Therapeutics

In other news, Director Peter A. Thompson sold 115,844 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the completion of the sale, the director owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. The trade was a 4.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 403,726 shares of company stock worth $18,259,354. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SION. Viking Global Investors LP boosted its holdings in shares of Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after acquiring an additional 242,427 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Sionna Therapeutics in the second quarter valued at approximately $64,875,000. Jennison Associates LLC increased its stake in shares of Sionna Therapeutics by 30.1% in the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after buying an additional 335,942 shares during the period. Vanguard Group Inc. raised its holdings in Sionna Therapeutics by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after buying an additional 41,797 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Sionna Therapeutics by 30.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock worth $34,203,000 after buying an additional 193,613 shares during the period.

Key Stories Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada upgraded Sionna Therapeutics from “underperform” to “sector perform,” while Stifel Nicolaus maintained a “hold” rating with a $7 price target. These actions suggest some analysts believe the post-trial selloff may have been excessive. Royal Bank of Canada upgrade
• Neutral Sentiment: Several firms moved to more cautious but non-bearish ratings, including “neutral,” “market perform,” “sector perform,” or “hold” from Wedbush, Guggenheim, Raymond James, BTIG, Lifesci Capital, JonesTrading, and Stifel. The broad analyst reset reflects substantially reduced expectations following the clinical setback. Analyst rating changes
• Negative Sentiment: Sionna reported that its lead candidate, SION-719, failed to meet the key endpoint in a Phase 2 cystic fibrosis trial. The company discontinued development of the drug as an add-on therapy, removing what had been its principal near-term opportunity to challenge Vertex Pharmaceuticals’ dominant CF franchise. Sionna halts SION-719
• Negative Sentiment: The trial failure has sharply damaged Sionna’s investment thesis, with reports describing the shares as down more than 90% and at a record or 12-month low. Investors are reassessing the company’s remaining pipeline, funding needs, and ability to create value without its lead program. Sionna trial failure and share decline
• Negative Sentiment: The concentrated analyst downgrades reinforce the bearish reaction: BTIG and Guggenheim shifted from buy ratings to neutral, while Raymond James, Wedbush, Lifesci Capital, and JonesTrading also reduced their recommendations. Wedbush and RBC both cited approximately $5 price targets, leaving limited near-term upside at the reported price. Sionna analyst downgrades

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.